Business Standard

'Indian R&D is depressing'

Related News

Prominent US-based IT businessman and philanthropist doesn’t have a high opinion of Indian research. In India last week to inaugurate a laboratory that he is funding, he expressed delight with the talent available in the country but was unhappy about the and the quality of research resulting from it. “Much of the research happening is not just boring, but outright depressing,” he was heard saying. That prompted one researcher to comment that, hopefully, Wadhwani’s high opinion of researchers won’t change — at least for the five years over which he is providing the Rs 7.5 crore towards research at the lab.

Read more on:   
|
|

'Indian R&D is depressing'

Prominent US-based IT businessman and philanthropist Romesh Wadhwani doesn’t have a high opinion of Indian research. In India last week to inaugurate a laboratory that he is funding, he expressed delight with the talent available in the country but was unhappy about the poor infrastructure and the quality of research resulting from it. “Much of the research happening is not just boring, but outright depressing,” he was heard saying.

Prominent US-based IT businessman and philanthropist doesn’t have a high opinion of Indian research. In India last week to inaugurate a laboratory that he is funding, he expressed delight with the talent available in the country but was unhappy about the and the quality of research resulting from it. “Much of the research happening is not just boring, but outright depressing,” he was heard saying. That prompted one researcher to comment that, hopefully, Wadhwani’s high opinion of researchers won’t change — at least for the five years over which he is providing the Rs 7.5 crore towards research at the lab.

image

Read More

Fruitful decision

After inaugurating the Centralised Processing Cell (CPC) for Tax Deducted at Source in Ghaziabad last week, Finance Minister P Chidambaram planted a ...

Recommended for you

Advertisements

Quick Links

Financial X-Ray Rss icon

M&M Q4 sales decline less than estimated

Higher realisations prevent sharper fall in sales, tractor margins down 300 bps to 11%

Ranbaxy: A new challenge for Sun Pharma

With Q4 performance already impacted, Sun Pharma needs to transform Ranbaxy's US and domestic operations

Back to Top